Cargando…

Prevention Surpasses Treatment: 5-year Follow-Up, Cost-Utility, and Cost–Benefit of Zeaxanthin Therapy for Neovascular Age-Related Macular Degeneration

INTRODUCTION: Oral administration of zeaxanthin (Zx) 20 mg daily in patients with unilateral neovascular age-related macular degeneration (nAMD) treated with triple therapy (photodynamic therapy/intravitreal bevacizumab/intravitreal dexamethasone) reduced fellow-eye 2-year nAMD incidence from 23 to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brown, Gary C., Brown, Melissa M., Gierhart, Dennis, Olk, R. Joseph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441916/ https://www.ncbi.nlm.nih.gov/pubmed/37430077 http://dx.doi.org/10.1007/s40123-023-00742-9

Ejemplares similares

Triple combination therapy and zeaxanthin for the treatment of neovascular age-related macular degeneration: an interventional comparative study and cost-effectiveness analysis
por: Olk, R. Joseph, et al.
Publicado: (2015)

A Value-Based Medicine cost-utility analysis of genetic testing for neovascular macular degeneration
por: Brown, Gary C., et al.
Publicado: (2015)

The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited
por: Brown, Gary C., et al.
Publicado: (2017)

Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration
por: Hurley, Susan F, et al.
Publicado: (2008)

Resource Utilization and Costs of Age-Related Macular Degeneration
por: Halpern, Michael T., et al.
Publicado: (2006)

Lutein and Zeaxanthin and Their Roles in Age-Related Macular Degeneration—Neurodegenerative Disease
por: Mrowicka, Małgorzata, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
por: Yanagi, Yasuo, et al.
Publicado: (2023)

Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
por: Yanagi, Yasuo, et al.
Publicado: (2023)

Modelling Cost Effectiveness in Neovascular Age-Related Macular Degeneration: The Impact of Using Contrast Sensitivity vs. Visual Acuity
por: Butt, Thomas, et al.
Publicado: (2014)

Macular pigment response to a supplement containing meso-zeaxanthin, lutein and zeaxanthin
por: Bone, Richard A, et al.
Publicado: (2007)

Lutein, Zeaxanthin and Meso-zeaxanthin Supplementation Associated with Macular Pigment Optical Density
por: Ma, Le, et al.
Publicado: (2016)

Direct Treatment Costs of Neovascular Age-related Macular Degeneration and Comparison of Gained and/or Preserved Vision with Expenditure
por: Yıldırım, Şeyda, et al.
Publicado: (2018)

Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis
por: Yu, Justin S, et al.
Publicado: (2021)

Real-World Injection Frequency and Cost of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
por: Kiss, Szilárd, et al.
Publicado: (2020)

Effects of Zeaxanthin on Growth and Invasion of Human Uveal Melanoma in Nude Mouse Model
por: Xu, Xiaoliang L., et al.
Publicado: (2015)

Histology of neovascular myopic macular degeneration
por: Jonas, Shefali B., et al.
Publicado: (2021)

A Systematic Review of Carotenoids in the Management of Age-Related Macular Degeneration
por: Lem, Drake W., et al.
Publicado: (2021)

Cost-Utility Analyses of Cataract Surgery in Advanced Age-Related Macular Degeneration
por: Ma, Yingyan, et al.
Publicado: (2016)

Lutein and Zeaxanthin—Food Sources, Bioavailability and Dietary Variety in Age-Related Macular Degeneration Protection
por: Eisenhauer, Bronwyn, et al.
Publicado: (2017)

Effect of Supplemental Lutein and Zeaxanthin on Serum, Macular Pigmentation, and Visual Performance in Patients with Early Age-Related Macular Degeneration
por: Huang, Yang-Mu, et al.
Publicado: (2015)

Daily zeaxanthin supplementation prevents atrophy of the retinal pigment epithelium (RPE) in a mouse model of mitochondrial oxidative stress
por: Biswal, Manas R., et al.
Publicado: (2018)

Cost-minimisation analysis of a treat-and-extend regimen with anti-VEGFs in patients with neovascular age-related macular degeneration
por: Quist, S. W., et al.
Publicado: (2021)

Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy
por: Ferrante, Nicola, et al.
Publicado: (2022)

Cost impact of different treatment regimens of brolucizumab in neovascular age-related macular degeneration: A budget impact analysis
por: Siddiqui, Zasim Azhar, et al.
Publicado: (2022)

Candidate gene study of macular response to supplemental lutein and zeaxanthin()
por: Yonova-Doing, Ekaterina, et al.
Publicado: (2013)

Ranibizumab in neovascular age-related macular degeneration
por: Eng, Kenneth T, et al.
Publicado: (2006)

Association of HDL-Related Loci with Age-Related Macular Degeneration and Plasma Lutein and Zeaxanthin: the Alienor Study
por: Merle, Bénédicte M. J., et al.
Publicado: (2013)

Pemafibrate prevents choroidal neovascularization in a mouse model of neovascular age-related macular degeneration
por: Lee, Deokho, et al.
Publicado: (2023)

Time and Distance Cost of Longer Acting Anti-VEGF Therapies for Macular Degeneration: Contributions to Drug Cost Comparisons
por: Meer, Elana A, et al.
Publicado: (2022)

Cost-effectiveness of smoking cessation to prevent age-related macular degeneration
por: Hurley, Susan F, et al.
Publicado: (2008)

Ranibizumab in neovascular age-related macular degeneration: a 5-year follow-up
por: Cvetkova, Nadezhda P, et al.
Publicado: (2016)

Healthcare Resource Utilization and Costs in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
por: Kim, Ashley, et al.
Publicado: (2021)

Vision protection therapy for prevention of neovascular age-related macular degeneration
por: Luttrull, Jeffrey K., et al.
Publicado: (2023)

Impact of Prophylactic Ranibizumab to Prevent Neovascular Age-Related Macular Degeneration on Eyes With Intermediate Age-Related Macular Degeneration
por: Chan, Clement K., et al.
Publicado: (2023)

Radiation therapy for neovascular age-related macular degeneration
por: Petrarca, Robert, et al.
Publicado: (2011)

Experimental Models in Neovascular Age Related Macular Degeneration
por: Rastoin, Olivia, et al.
Publicado: (2020)

Pipeline therapies for neovascular age related macular degeneration
por: Arepalli, Sruthi, et al.
Publicado: (2021)

Association of neovascular age-related macular degeneration with migraine
por: Kuang, Tung-Mei, et al.
Publicado: (2022)

Home Monitoring of Age-Related Macular Degeneration: Utility of the ForeseeHome Device for Detection of Neovascularization
por: Yu, Hannah J., et al.
Publicado: (2020)

Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes
por: Blazaki, Styliani, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kmd9he0pg4hp9hm5314ncmohgg